|
1. |
Substance Abuse in Patients with Attention-Deficit Hyperactivity DisorderTherapeutic Implications |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 643-655
Howard Schubiner,
Preview
|
PDF (206KB)
|
|
摘要:
Attention-deficit hyperactivity disorder (ADHD) is a common disorder in children that frequently persists into adulthood. Studies have found that substance use disorders (SUD) are seen more commonly in those with ADHD than the general population. Although treatment with stimulant medications has been shown to be effective for individuals with ADHD, concern about the use of these agents in this population persists. This review article highlights the research in this area with a focus on the treatment of individuals who present with concomitant ADHD and SUD.Although stimulants can be abused, studies have shown that adolescents who are prescribed stimulants for ADHD have lower rates of SUD than those who are not treated with stimulants.It may be particularly difficult to evaluate adults for the diagnosis of ADHD when SUD is a co-morbid factor. Studies show that 20–30% of adults presenting with SUD have concomitant ADHD and approximately 20–40% of adults with ADHD have histories of SUD. Therefore, it is critical to perform careful diagnostic interviews to discern if patients have either or both of these disorders. Many clinical experts suggest that adults with ADHD and active SUD be treated for the SUD until a period of sobriety persists prior to initiation of specific treatment for ADHD. Since individuals with ADHD and active SUD are more likely to have more severe SUD and a worse prognosis, this approach may not serve many patients, as they relapse prior to obtaining ADHD treatment. Therefore, research has been directed towards determining if the treatment of ADHD with stimulant medications can be safe and effective for the individual with active SUD and concomitant ADHD. An initial trial of methylphenidate in a population of adults with active cocaine dependence and ADHD indicates that this is the case.Individuals with ADHD and SUD can present difficult diagnostic and therapeutic challenges. It appears that the most effective treatment option is to create a programme that uses the most effective treatment modalities available, including both behavioural and medical therapies, along with close supervision and monitoring. Newer medical treatment options of long-acting stimulants and non-stimulants (e.g. atomoxetine) offer effective treatment with a lower risk of abuse potential.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
2. |
ErotomaniaEpidemiology and Management |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 657-669
Brendan D Kelly,
Preview
|
PDF (257KB)
|
|
摘要:
Erotomania is generally classified as a delusional disorder in contemporary classification systems (DSM-IV and ICD-10). The incidence of erotomania is not known, but that of delusional disorder in general has been reported as approximately 15 cases per 100 000 of the population per year, with a female : male ratio of 3 : 1. Both primary and secondary types of erotomania have been identified, the latter being associated with evidence of an aetiologically significant organic or psychiatric condition. The aetiology of primary erotomania is not yet fully understood, but neuroimaging, genetic studies and findings from evolutionary psychopathology hold considerable promise for a deeper and broader understanding of this condition.The initial management of secondary erotomania focuses on treating the underlying organic or psychiatric illness. The management of primary and secondary erotomania involves a combination of pharmacological treatments, psychosocial interventions and risk management strategies. In the past, the antipsychotic medication pimozide was commonly used, at least in certain countries (such as the US and Canada), despite a paucity of systematic studies of its use in this disorder. In recent years, there have been reports of positive therapeutic outcomes with atypical antipsychotics (risperidone, clozapine), which, as a result of their improved tolerability over older agents such as pimozide, will hopefully enhance patient acceptability and, thereby, improve clinical outcome. Despite this advance, there is still a strong need for controlled clinical trials of therapeutic strategies for primary erotomania and related syndromes.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
3. |
AIDS-Associated Progressive Multifocal LeukoencephalopathyCurrent Management Strategies |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 671-682
Mark T M Roberts,
Preview
|
PDF (225KB)
|
|
摘要:
Progressive multifocal leukoencephalopathy (PML) is a rare, opportunistic infection of the CNS by the ubiquitous JC virus (JCV). PML is only seen in the context of severe and prolonged immunosuppression, a phenomenon now frequently encountered since the AIDS pandemic. PML is characterised by progressive lysis of oligodendrocytes with demyelination. A rapid clinical course ensues with focal neurological deficits and a median time to death of 3.5 months without treatment. Prior to highly active antiretroviral therapy (HAART), there was no effective therapy. Since the advent of HAART, the prognosis for PML has much improved; however, a significant number of patients appear unresponsive to antiretrovirals and some worsen because of the development of immune reconstitution disease. A better understanding of the biology of JCV and its interactions with host cells is leading to new anti-JCV-specific agents that await evaluation in randomised, controlled trials. Improved diagnostic tools and the possibility of immunotherapy and gene therapy are further advancing the field.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
4. |
The Risk of Stroke in Patients with Migraine and Implications for Migraine Management |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 683-692
Gretchen E Tietjen,
Preview
|
PDF (194KB)
|
|
摘要:
Assessing the risk of stroke in persons with migraine is complicated by the intricate relationship between these two conditions. Both migraine and stroke are common and co-morbidity may, in some cases, be coincidental. Given the overlap of clinical symptoms in stroke and migraine, each condition may also mimic the other. Numerous studies have, however, shown that migraine is an independent risk factor for stroke both during, and remote from, the migraine attack. Women of childbearing age and those with aura are at greatest risk of migraine-related stroke. Additional risk of stroke in migraineurs occurs in those using oral contraceptive pills and who smoke cigarettes. Elevated blood pressure, an important stroke risk factor, is less common in migraineurs. Acquired antiphospholipid antibodies, not clearly a cause of migraineper se, may raise the risk of infarction in migraineurs. Hereditary conditions, including CADASIL (cerebral autosomal dominant arteriopathy with sub-cortical infarcts and leukoencephalopathy), MELAS (mitochondrial myopathy, encephalopathy, lactacidosis and stroke) and hereditary haemorrhagic telangiectasia, appear to predispose to both migraine and stroke. Purported mechanisms for migraine-associated stroke include involvement of the vasculature (including vasospasm, arterial dissection and small vessel arteriopathy), hypercoagulability (elevated von Willebrand Factor, platelet activation) and elevated risk of cardioembolism (patent foramen ovale, atrial septal aneurysm). Triptans and ergotamines, used to treat acute migraine attacks, appear to be safe in low-risk populations. These medications should be avoided in persons with haemiplegic migraine, basilar migraine, vascular risk factor and prior cerebral or cardiac ischaemia.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
5. |
The Opioidergic-Alcohol LinkImplications for Treatment |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 693-707
Vania Modesto-Lowe,
Eleanor M Fritz,
Preview
|
PDF (249KB)
|
|
摘要:
Preclinical and clinical data implicate the endogenous opioid system in alcohol dependence.In vitrostudies show that rodent pituitary and hypothalamic tissue responds to acute exposure to alcohol by releasing β-endorphins.In vivostudies suggest differential activity of endogenous opioid receptors in rodents with high and low alcohol preference. Similarly, humans with a family history of alcohol dependence also show a heightened endorphin response to an acute challenge of alcohol compared with those with no family history of alcohol dependence.The effects of opioid agonists and antagonists on rodent and human alcohol consumption further support the opioid-alcohol link. In rodents and humans, small doses of opioid agonists increase alcohol consumption, while pretreatment with large doses decreases consumption. The opioid antagonist naltrexone decreases rodent alcohol consumption, particularly in low doses under acute and intermittent schedules.Most clinical trials in patients with alcohol dependence support modest therapeutic effects of naltrexone in decreasing alcohol consumption. Efforts to identify subgroups of alcohol-dependent patients responsive to naltrexone, as well as psychosocial and pharmacological augmentation strategies, may further improve the clinical usefulness of the drug.
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
6. |
Extended-Release Carbamazepine CapsulesIn Bipolar I Disorder |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 709-716
Tracy Swainston Harrison,
Gillian M Keating,
Preview
|
PDF (252KB)
|
|
摘要:
▴ An extended-release capsule formulation of carbamazepine is approved for use in adult patients experiencing an acute manic or mixed episode associated with bipolar I disorder. A capsule of extended-release carbamazepine contains three types of bead: immediate release, extended release and enteric release, constituting 25%, 40% and 35% of the dose, respectively.▴ Extended-release carbamazepine capsules 200–1600 mg/day demonstrated superior antimanic efficacy to placebo in two 3-week, well designed trials in adult patients with bipolar I disorder and acute manic or mixed episodes. At study end, reductions from baseline in Young Mania Rating Scale scores were significantly greater with carbamazepine than with placebo (primary endpoint). The active treatment was effective from the end of the first week of treatment (post hocanalysis).▴ In the 3-week trials and a 6-month extension study, most treatment-emergent adverse events observed with extended-release carbamazepine were of mild or moderate severity. In the 3-week trials, although significantly greater reductions in white blood cell count occurred with extended-release carbamazepine than with placebo, only one case of leukopenia was deemed serious. There were no reports of agranulocytosis or aplastic anaemia with up to 6 months' treatment.Table. Features and properties of extended-release carbamazepine capsules (Equetro™)
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
7. |
Extended-Release Carbamazepine CapsulesA Viewpoint by Philip B. Mitchell |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 717-718
Philip B Mitchell,
Preview
|
PDF (123KB)
|
|
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
8. |
Interferon-α Treatment of Patients with Hepatitis C |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 719-721
Muhamad Aly Rifai,
Jennifer M Loftis,
Peter Hauser,
Preview
|
PDF (148KB)
|
|
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
9. |
The Authors’ Reply |
|
CNS Drugs,
Volume 19,
Issue 8,
2005,
Page 721-722
Charles L Raison,
Marina Demetrashvili,
Lucile Capuron,
Andrew H Miller,
Preview
|
PDF (139KB)
|
|
ISSN:1172-7047
出版商:ADIS
年代:2005
数据来源: ADIS
|
|